Literature DB >> 25956404

Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification.

Jun Li1, Qing Wang1, Zhengqing Lei1, Dong Wu1, Anfeng Si1, Kui Wang1, Xuying Wan1, Yizhou Wang1, Zhenlin Yan1, Yong Xia1, Wan Yee Lau1, Mengchao Wu1, Feng Shen2.   

Abstract

BACKGROUND: The effectiveness of adjuvant transarterial chemoembolization (TACE) for intrahepatic cholangiocarcinoma (ICC) after hepatectomy remains unclear. This study was performed to identify ICC patients who would benefit from adjuvant TACE. PATIENTS AND METHODS: The study included 553 patients who underwent hepatectomy for ICC between January 2008 and February 2011 at the Eastern Hepatobiliary Surgery Hospital and who were treated with or without TACE (122 with TACE and 431 without TACE). Survival risk stratification was performed using the established prognostic nomogram (ICC nomogram). The predictive performance was evaluated by concordance index and calibration. The tumor recurrence and overall survival (OS) rates were analyzed by the Kaplan-Meier method before and after propensity score matching (PSM).
RESULTS: The predictive performance of the ICC nomogram was demonstrated by the well-fitted calibration curves and an optimal c-index of 0.71 for OS prediction. In the whole cohort, the 5-year recurrence and OS rates between the TACE and non-TACE groups were significantly different (5-year recurrence: 72.9% vs. 78.1%; OS: 38.4% vs. 29.7%). After 1:1 PSM, the TACE and non-TACE groups (122 patients each) had similar 5-year recurrence and OS rates (5-year recurrence: 72.9% vs. 74.2%; OS: 38.4% vs. 36.0%). By survival risk stratification based on ICC nomogram, only the patients in the lowest tertile (nomogram scores ≥77) benefited from adjuvant TACE (TACE vs. non-TACE groups: 90.4% vs. 95.9% for 5-year recurrence; 21.3% vs. 6.2% for 5-year OS).
CONCLUSION: Adjuvant TACE following liver resection might be suitable for ICC patients with high ICC nomogram scores (≥77). IMPLICATIONS FOR PRACTICE: The accurate predictive performance of the established prognostic nomogram for intrahepatic cholangiocarcinoma (ICC) following liver resection was reconfirmed in an independent cohort with 553 patients. Based on the survival risk stratification using the nomogram, adjuvant transarterial chemoembolization following liver resection might be suitable only for ICC patients with high scores from the nomogram. ©AlphaMed Press.

Entities:  

Keywords:  Adjuvant transarterial chemoembolization; Hepatectomy; Intrahepatic cholangiocarcinoma; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 25956404      PMCID: PMC4571785          DOI: 10.1634/theoncologist.2014-0470

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  29 in total

Review 1.  Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature.

Authors:  Murad Aljiffry; Alhawsawi Abdulelah; Mark Walsh; Kevork Peltekian; Ian Alwayn; Michele Molinari
Journal:  J Am Coll Surg       Date:  2008-10-31       Impact factor: 6.113

2.  Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.

Authors:  Mechteld C de Jong; Hari Nathan; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Cristina R Ferrone; Andrew X Zhu; Todd W Bauer; Dustin M Walters; T Clark Gamblin; Kevin T Nguyen; Ryan Turley; Irinel Popescu; Catherine Hubert; Stephanie Meyer; Richard D Schulick; Michael A Choti; Jean-Francois Gigot; Gilles Mentha; Timothy M Pawlik
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Authors:  Stephen B Edge; Carolyn C Compton
Journal:  Ann Surg Oncol       Date:  2010-06       Impact factor: 5.344

5.  A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score.

Authors:  W Jiang; Z-C Zeng; Z-Y Tang; J Fan; H-C Sun; J Zhou; M-S Zeng; B-H Zhang; Y Ji; Y-X Chen
Journal:  Ann Oncol       Date:  2011-01-06       Impact factor: 32.976

6.  A proposed staging system for intrahepatic cholangiocarcinoma.

Authors:  Hari Nathan; Thomas A Aloia; Jean-Nicolas Vauthey; Eddie K Abdalla; Andrew X Zhu; Richard D Schulick; Michael A Choti; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2008-11-06       Impact factor: 5.344

7.  Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.

Authors:  Itaru Endo; Mithat Gonen; Adam C Yopp; Kimberly M Dalal; Qin Zhou; David Klimstra; Michael D'Angelica; Ronald P DeMatteo; Yuman Fong; Lawrence Schwartz; Nancy Kemeny; Eileen O'Reilly; Ghassan K Abou-Alfa; Hiroshi Shimada; Leslie H Blumgart; William R Jarnagin
Journal:  Ann Surg       Date:  2008-07       Impact factor: 12.969

8.  Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis.

Authors:  Hari Nathan; Timothy M Pawlik; Christopher L Wolfgang; Michael A Choti; John L Cameron; Richard D Schulick
Journal:  J Gastrointest Surg       Date:  2007-09-05       Impact factor: 3.452

9.  Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma.

Authors:  Dietmar Tamandl; Beata Herberger; Birgit Gruenberger; Harald Puhalla; Markus Klinger; Thomas Gruenberger
Journal:  Ann Surg Oncol       Date:  2008-08-07       Impact factor: 5.344

10.  Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging.

Authors:  Ji Y Kim; Myung-Hwan Kim; Tae Y Lee; Chang Y Hwang; Jae S Kim; Sung-Cheol Yun; Sang S Lee; Dong W Seo; Sung K Lee
Journal:  Am J Gastroenterol       Date:  2008-01-02       Impact factor: 10.864

View more
  21 in total

Review 1.  Surgical options for intrahepatic cholangiocarcinoma.

Authors:  Kui Wang; Han Zhang; Yong Xia; Jian Liu; Feng Shen
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

Review 2.  Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.

Authors:  Xing Chen; Jinpeng Du; Jiwei Huang; Yong Zeng; Kefei Yuan
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

Review 3.  The focus clinical research in intrahepatic cholangiocarcinoma.

Authors:  Yinghui Song; Mengting Cai; Yuhang Li; Sulai Liu
Journal:  Eur J Med Res       Date:  2022-07-11       Impact factor: 4.981

4.  Postoperative adjuvant transarterial chemoembolization for intrahepatic cholangiocarcinoma patients with microvascular invasion: a propensity score analysis.

Authors:  Zhangjun Cheng; Zhengqing Lei; Xiaoling Jin; Qi Zhang; Anfeng Si; Pinghua Yang; Jiahua Zhou; Daniel Hartmann; Norbert Hüser; Feng Shen
Journal:  J Gastrointest Oncol       Date:  2021-04

5.  Novel Nomogram for Preoperative Prediction of Early Recurrence in Intrahepatic Cholangiocarcinoma.

Authors:  Wenjie Liang; Lei Xu; Pengfei Yang; Lele Zhang; Dalong Wan; Qiang Huang; Tianye Niu; Feng Chen
Journal:  Front Oncol       Date:  2018-09-04       Impact factor: 6.244

6.  HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.

Authors:  Chu-Yu Jing; Yi-Peng Fu; Yong Yi; Mei-Xia Zhang; Su-Su Zheng; Jin-Long Huang; Wei Gan; Xin Xu; Jia-Jia Lin; Juan Zhang; Shuang-Jian Qiu; Bo-Heng Zhang
Journal:  J Immunother Cancer       Date:  2019-03-18       Impact factor: 13.751

Review 7.  The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma.

Authors:  Guergana Panayotova; Jarot Guerra; James V Guarrera; Keri E Lunsford
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

Review 8.  Interventional Treatment for Cholangiocarcinoma.

Authors:  Hang Li; Li Chen; Guang-Yu Zhu; Xijuan Yao; Rui Dong; Jin-He Guo
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

Review 9.  Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.

Authors:  Yun Shin Chun; Milind Javle
Journal:  Cancer Control       Date:  2017 Jul-Sep       Impact factor: 3.302

10.  Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.

Authors:  Wei-Ren Liu; Meng-Xin Tian; Chen-Yang Tao; Zheng Tang; Yu-Fu Zhou; Shu-Shu Song; Xi-Fei Jiang; Han Wang; Pei-Yun Zhou; Wei-Feng Qu; Yuan Fang; Zhen-Bin Ding; Jian Zhou; Jia Fan; Ying-Hong Shi
Journal:  BMC Cancer       Date:  2020-07-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.